Michael Quigley, Ph.D. is currently the Chief Scientific Officer and Global Head of Research at Sanofi with responsibility for Sanofi’s main therapeutic research areas of Immunology & Inflammation, Oncology including Immuno-Oncology, Neurology and Rare Diseases with a mandate to innovate and accelerate first and best in class medicines from discovery to clinical translation.

Before joining Sanofi, Mike was Co-Founder, President and Chief Executive Officer of Dualitas Therapeutics, a biotech company focused on a novel proprietary platform to unlock and develop next generation bispecific antibody medicines towards therapeutic gain across a range of indications. Mike was also a Venture Partner with SV Health Investors and previously served as Chief Executive Officer of Therini Bio. Prior to joining biotech, Mike was Senior Vice President of Research Biology at Gilead Sciences, overseeing the Company’s biology teams and preclinical portfolio as well as protein biotherapeutics and computational biology efforts across all therapeutic areas. Prior to that, he was Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center at Bristol Myers Squibb and site head of the Company’s Redwood City, California location. Earlier in his career Mike led teams in Oncology Discovery at MedImmune and Janssen. Mike received his PhD in Immunology at Duke University and completed his postdoctoral studies at the Dana-Farber Cancer Institute, Department of Pediatric Oncology.